Tokyo Tape
Sign in
← H.U. Group Holdings

Quarterly report · Q3

4544.TEDINET S100SUU5
Period2023-04-01 → 2023-12-31
Filed2024-02-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 48
MetricValuePeriodScopeSource row
Revenue¥177.5bn2023-04-01 → 2023-12-31Cons.Net sales
Revenue¥260.9bn2022-04-01 → 2023-03-31Cons.Net sales (5-year summary)
Revenue¥201.0bn2022-04-01 → 2022-12-31Cons.Net sales
Operating income−¥1.1bn2023-04-01 → 2023-12-31Cons.Operating income
Operating income¥23.7bn2022-04-01 → 2022-12-31Cons.Operating income
Ordinary income−¥2.9bn2023-04-01 → 2023-12-31Cons.Ordinary income
Ordinary income¥22.0bn2022-04-01 → 2023-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥23.2bn2022-04-01 → 2022-12-31Cons.Ordinary income
Profit before tax−¥3.2bn2023-04-01 → 2023-12-31Cons.Income before income taxes
Profit before tax¥25.8bn2022-04-01 → 2022-12-31Cons.Income before income taxes
Net income (owners)−¥3.3bn2023-04-01 → 2023-12-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥15.7bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥18.8bn2022-04-01 → 2022-12-31Cons.Profit loss attributable to owners of parent
Net income−¥3.3bn2023-04-01 → 2023-12-31Cons.Profit loss
Net income¥18.8bn2022-04-01 → 2022-12-31Cons.Profit loss
Total assets¥284.1bnat 2023-12-31Cons.Assets
Total assets¥297.9bnat 2023-03-31Cons.Assets
Total assets¥281.9bnat 2022-12-31Cons.Total assets (5-year summary)
Total liabilities¥140.9bnat 2023-12-31Cons.Liabilities
Total liabilities¥147.9bnat 2023-03-31Cons.Liabilities
Net assets / equity¥143.2bnat 2023-12-31Cons.Net assets
Net assets / equity¥150.0bnat 2023-03-31Cons.Net assets
Net assets / equity¥153.3bnat 2022-12-31Cons.Net assets (5-year summary)
Cash and deposits¥40.4bnat 2023-12-31Cons.Cash and deposits
Cash and deposits¥44.2bnat 2023-03-31Cons.Cash and deposits
Cash & equivalents¥40.4bnat 2023-12-31Cons.Cash and cash equivalents
Cash & equivalents¥44.2bnat 2023-03-31Cons.Cash and cash equivalents
Cash & equivalents¥30.5bnat 2022-12-31Cons.Cash and cash equivalents
Cash & equivalents¥46.5bnat 2022-03-31dCons.Cash and cash equivalents
Operating cash flow¥9.4bn2023-04-01 → 2023-12-31Cons.Net cash provided by used in operating activities
Operating cash flow¥32.5bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥19.2bn2022-04-01 → 2022-12-31Cons.Net cash provided by used in operating activities
Investing cash flow−¥9.2bn2023-04-01 → 2023-12-31Cons.Net cash provided by used in investment activities
Investing cash flow−¥29.6bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥24.9bn2022-04-01 → 2022-12-31Cons.Net cash provided by used in investment activities
Financing cash flow−¥4.6bn2023-04-01 → 2023-12-31Cons.Net cash provided by used in financing activities
Financing cash flow−¥5.8bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥10.9bn2022-04-01 → 2022-12-31Cons.Net cash provided by used in financing activities
EPS (basic)¥-58.782023-04-01 → 2023-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-26.782023-10-01 → 2023-12-31dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥275.522022-04-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥331.222022-04-01 → 2022-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥57.352022-10-01 → 2022-12-31dCons.Basic earnings loss per share (5-year summary)
EPS (diluted)¥275.52022-04-01 → 2023-03-31Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥331.192022-04-01 → 2022-12-31Cons.Diluted earnings per share (5-year summary)
Equity ratio50.4%at 2023-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio50.3%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio54.4%at 2022-12-31Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 38
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-12-31−¥4.5bn
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-12-31−¥4.5bn
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-12-31−¥4.6bn
jpcrp040300-q3r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue2023-04-01 → 2023-12-31¥110.2bn
jpcrp040300-q3r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue external2023-04-01 → 2023-12-31¥110.0bn
jpcrp040300-q3r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue intersegment2023-04-01 → 2023-12-31¥214m
jpcrp040300-q3r_E00967-000Clinical Lab Testing Businessreportable segmentsegment profit2023-04-01 → 2023-12-31−¥8.6bn
jpcrp040300-q3r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue2023-04-01 → 2023-12-31¥50.7bn
jpcrp040300-q3r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue external2023-04-01 → 2023-12-31¥46.4bn
jpcrp040300-q3r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue intersegment2023-04-01 → 2023-12-31¥4.3bn
jpcrp040300-q3r_E00967-000In Vitro Diagnostics Businessreportable segmentsegment profit2023-04-01 → 2023-12-31¥11.0bn
jpcrp040300-q3r_E00967-000Sterilization And Related Servicesreportable segmentrevenue2023-04-01 → 2023-12-31¥21.1bn
jpcrp040300-q3r_E00967-000Sterilization And Related Servicesreportable segmentrevenue external2023-04-01 → 2023-12-31¥21.1bn
jpcrp040300-q3r_E00967-000Sterilization And Related Servicesreportable segmentrevenue intersegment2023-04-01 → 2023-12-31¥4m
jpcrp040300-q3r_E00967-000Sterilization And Related Servicesreportable segmentsegment profit2023-04-01 → 2023-12-31¥938m
—segment totalrevenue2023-04-01 → 2023-12-31¥182.0bn
—segment totalrevenue external2023-04-01 → 2023-12-31¥177.5bn
—segment totalrevenue intersegment2023-04-01 → 2023-12-31¥4.5bn
—segment totalsegment profit2023-04-01 → 2023-12-31¥3.4bn
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-12-31−¥6.2bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-12-31−¥6.2bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-12-31−¥3.3bn
jpcrp040300-q3r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue2022-04-01 → 2022-12-31¥124.9bn
jpcrp040300-q3r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue external2022-04-01 → 2022-12-31¥124.7bn
jpcrp040300-q3r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥212m
jpcrp040300-q3r_E00967-000Clinical Lab Testing Businessreportable segmentsegment profit2022-04-01 → 2022-12-31¥2.7bn
jpcrp040300-q3r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue2022-04-01 → 2022-12-31¥61.6bn
jpcrp040300-q3r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue external2022-04-01 → 2022-12-31¥55.6bn
jpcrp040300-q3r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥5.9bn
jpcrp040300-q3r_E00967-000In Vitro Diagnostics Businessreportable segmentsegment profit2022-04-01 → 2022-12-31¥23.5bn
jpcrp040300-q3r_E00967-000Sterilization And Related Servicesreportable segmentrevenue2022-04-01 → 2022-12-31¥20.7bn
jpcrp040300-q3r_E00967-000Sterilization And Related Servicesreportable segmentrevenue external2022-04-01 → 2022-12-31¥20.6bn
jpcrp040300-q3r_E00967-000Sterilization And Related Servicesreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥15m
jpcrp040300-q3r_E00967-000Sterilization And Related Servicesreportable segmentsegment profit2022-04-01 → 2022-12-31¥825m
—segment totalrevenue2022-04-01 → 2022-12-31¥207.1bn
—segment totalrevenue external2022-04-01 → 2022-12-31¥201.0bn
—segment totalrevenue intersegment2022-04-01 → 2022-12-31¥6.2bn
—segment totalsegment profit2022-04-01 → 2022-12-31¥26.9bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 485
ItemContextValueUnit
Proceeds from sales of property plant and equipment inv cfPrior1YTDDuration2677000000JPY
Proceeds from sales of property plant and equipment inv cfCurrentYTDDuration1135000000JPY
Purchase of intangible assets inv cfPrior1YTDDuration-6218000000JPY
Purchase of intangible assets inv cfCurrentYTDDuration-4187000000JPY
Purchase of investments in subsidiaries inv cfPrior1YTDDuration-8983000000JPY
Purchase of investments in subsidiaries inv cfCurrentYTDDuration－JPY
Payments for investments in capital inv cfPrior1YTDDuration-563000000JPY
Payments for investments in capital inv cfCurrentYTDDuration-529000000JPY
Proceeds from collection of guarantee deposits inv cfPrior1YTDDuration124000000JPY
Proceeds from collection of guarantee deposits inv cfCurrentYTDDuration528000000JPY
Other net inv cfPrior1YTDDuration-1303000000JPY
Other net inv cfCurrentYTDDuration292000000JPY
Net cash provided by used in investment activitiesPrior1YTDDuration-24859000000JPY
Net cash provided by used in investment activitiesCurrentYTDDuration-9159000000JPY
Proceeds from long term loans payable fin cfPrior1YTDDuration－JPY
Proceeds from long term loans payable fin cfCurrentYTDDuration4000000000JPY
Repayment of long term loans payable fin cfPrior1YTDDuration-3621000000JPY
Repayment of long term loans payable fin cfCurrentYTDDuration-3700000000JPY
Proceeds from issuance of bonds fin cfPrior1YTDDuration－JPY
Proceeds from issuance of bonds fin cfCurrentYTDDuration6100000000JPY
Purchase of treasury stock fin cfPrior1YTDDuration-1000000JPY
Purchase of treasury stock fin cfCurrentYTDDuration-987000000JPY
Cash dividends paid fin cfPrior1YTDDuration-7118000000JPY
Cash dividends paid fin cfCurrentYTDDuration-7123000000JPY
Net increase decrease in short term loans payable fin cfPrior1YTDDuration3000000000JPY
Net increase decrease in short term loans payable fin cfCurrentYTDDuration－JPY
Repayments of finance lease obligations fin cfPrior1YTDDuration-3190000000JPY
Repayments of finance lease obligations fin cfCurrentYTDDuration-3235000000JPY
Other net fin cfPrior1YTDDuration77000000JPY
Other net fin cfCurrentYTDDuration371000000JPY
Net cash provided by used in financing activitiesPrior1YTDDuration-10854000000JPY
Net cash provided by used in financing activitiesCurrentYTDDuration-4575000000JPY
Effect of exchange rate change on cash and cash equivalentsPrior1YTDDuration526000000JPY
Effect of exchange rate change on cash and cash equivalentsCurrentYTDDuration576000000JPY
Net increase decrease in cash and cash equivalentsPrior1YTDDuration-15999000000JPY
Net increase decrease in cash and cash equivalentsCurrentYTDDuration-3783000000JPY
Cash and cash equivalentsPrior2YearInstant46479000000JPY
Cash and cash equivalentsPrior1YearInstant44185000000JPY
Cash and cash equivalentsPrior1QuarterInstant30480000000JPY
Cash and cash equivalentsCurrentQuarterInstant40402000000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q3r_E00967-000ClinicalLabTestingBusinessReportableSegmentsMember124705000000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q3r_E00967-000InVitroDiagnosticsBusinessReportableSegmentsMember55616000000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q3r_E00967-000SterilizationAndRelatedServicesReportableSegmentsMember20641000000JPY
Revenues from external customersPrior1YTDDuration_ReportableSegmentsMember200963000000JPY
Revenues from external customersPrior1YTDDuration_ReconcilingItemsMember－JPY
Revenues from external customersPrior1YTDDuration200963000000JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q3r_E00967-000ClinicalLabTestingBusinessReportableSegmentsMember212000000JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q3r_E00967-000InVitroDiagnosticsBusinessReportableSegmentsMember5939000000JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q3r_E00967-000SterilizationAndRelatedServicesReportableSegmentsMember15000000JPY
Transactions with other segmentsPrior1YTDDuration_ReportableSegmentsMember6167000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2023-03-31pass
balance sheet identityconsolidated 2023-12-31pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsconsolidated 2023-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-12-31pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-12-31pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-12-31pass
statement vs summary · revenueconsolidated 2022-04-01/2022-12-31pass
statement vs summary · revenueconsolidated 2023-04-01/2023-12-31pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-12-31pass